Stocktwits on MSN2d
BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously Optimistic
U.S.-listed shares of BioNTech SE ended Monday nearly 3.2% lower, weighed down by a weak full-year revenue projection even as ...
BioNTech SE (BNTX) Gets a Buy from Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...
BioNTech SE 4Q Profit Declines as Demand for Covid-19 Vaccines Wanes
"We expect 2025 to be a data-rich year with multiple important updates from our priority programs," said Chief Executive Ugur Sahin. BioNTech forecast revenue between 1.7 billion euros and 2.2 billion ...
Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...
Goldman Sachs Sticks to Its Buy Rating for BioNTech SE (BNTX)
In a report released today, Chris Shibutani from Goldman Sachs maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...
Seeking Alpha2d
BioNTech SE (BNTX) Q4 2024 Earnings Call Transcript
Welcome to BioNTech's Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations. Please go ahead. Thank you.